Fluorescein Lisicol

Summary

Fluorescein Lisicol (CHEMBL2107751) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 9
• Chemistry: 926.1 Da · C51H63N3O11S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107751
Name	Fluorescein Lisicol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	70697664
Molecular formula	C51H63N3O11S
Molecular weight	926.1
InChIKey	KHNJPPGHIWPDLG-DXNXUNFASA-N

SMILES: C[C@H](CCC(=O)N[C@@H](CCCCNC(=S)NC1=CC2=C(C=C1)C3(C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O)OC2=O)C(=O)O)[C@H]6CC[C@@H]7[C@@]6([C@H](C[C@H]8[C@H]7[C@@H](C[C@H]9[C@@]8(CC[C@H](C9)O)C)O)O)C

IUPAC name: (2S)-6-[(3’,6’-dihydroxy-3-oxospiro[2-benzofuran-1,9’-xanthene]-5-yl)carbamothioylamino]-2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]hexanoic acid

Also known as: Cholyl-lysl-fluorescein, Fluorescein lisicol, Fluoresceina lisicol, Fluoresceine lisicol, NRL-972, Nrl972, NRL972, FLUORESCEIN LISICOL

Patent coverage: 2 distinct patent families (2 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	5
PHASE2	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00794482	PHASE3	COMPLETED	Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
NCT00794716	PHASE2	COMPLETED	PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT00856869	PHASE1/PHASE2	COMPLETED	Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
NCT00915057	PHASE2	COMPLETED	Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.
NCT00856713	PHASE1	COMPLETED	Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers
NCT00856752	PHASE1	COMPLETED	Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine
NCT00857480	PHASE1	COMPLETED	Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin
NCT00896597	PHASE1	COMPLETED	Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis
NCT01164332	PHASE1	COMPLETED	Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).